CYCLACEL PHARMACEUTICALS INC (CYCC)
US23254L8019 - Common Stock
Overall CYCC gets a fundamental rating of 2 out of 10. We evaluated CYCC against 565 industry peers in the Biotechnology industry. CYCC may be in some trouble as it scores bad on both profitability and health. CYCC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CYCC had negative earnings in the past year.
In the past year CYCC has reported a negative cash flow from operations.
CYCC had negative earnings in each of the past 5 years.
CYCC had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -250.53%, CYCC is doing worse than 92.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -250.53% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-127.03%
ROA(5y)-93.46%
ROE(3y)-1302.39%
ROE(5y)-802.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CYCC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CYCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYCC has less shares outstanding than it did 1 year ago.
The number of shares outstanding for CYCC has been increased compared to 5 years ago.
CYCC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CYCC has an Altman-Z score of -123.32. This is a bad value and indicates that CYCC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -123.32, CYCC is doing worse than 97.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -123.32 |
ROIC/WACCN/A
WACC10.43%
2.3 Liquidity
CYCC has a Current Ratio of 0.77. This is a bad value and indicates that CYCC is not financially healthy enough and could expect problems in meeting its short term obligations.
CYCC's Current ratio of 0.77 is on the low side compared to the rest of the industry. CYCC is outperformed by 90.20% of its industry peers.
A Quick Ratio of 0.77 indicates that CYCC may have some problems paying its short term obligations.
CYCC's Quick ratio of 0.77 is on the low side compared to the rest of the industry. CYCC is outperformed by 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
CYCC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -164.37%.
The Revenue for CYCC has decreased by -80.83% in the past year. This is quite bad
CYCC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.87% yearly.
EPS 1Y (TTM)-164.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.5%
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y22.87%
Sales Q2Q%-37.5%
3.2 Future
The Earnings Per Share is expected to grow by 19.55% on average over the next years. This is quite good.
Based on estimates for the next years, CYCC will show a very strong growth in Revenue. The Revenue will grow by 233.26% on average per year.
EPS Next Y88.28%
EPS Next 2Y38.76%
EPS Next 3Y24.73%
EPS Next 5Y19.55%
Revenue Next Year-88.95%
Revenue Next 2Y-64.15%
Revenue Next 3Y-36.42%
Revenue Next 5Y233.26%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CYCC. In the last year negative earnings were reported.
Also next year CYCC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CYCC's earnings are expected to grow with 24.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.76%
EPS Next 3Y24.73%
5. Dividend
5.1 Amount
No dividends for CYCC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYCLACEL PHARMACEUTICALS INC
NASDAQ:CYCC (11/22/2024, 4:30:00 PM)
After market: 0.3512 0 (-1.35%)0.356
+0.01 (+2.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap701.32K
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -250.53% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.77 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-164.37%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y88.28%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-80.83%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y